This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bhavnani, S. M.
Right arrow Articles by Ambrose, P. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bhavnani, S. M.
Right arrow Articles by Ambrose, P. G.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, September 2005, p. 3944-3947, Vol. 49, No. 9
0066-4804/05/$08.00+0     doi:10.1128/AAC.49.9.3944-3947.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.

Use of Pharmacokinetic-Pharmacodynamic Target Attainment Analyses To Support Phase 2 and 3 Dosing Strategies for Doripenem

Sujata M. Bhavnani,1,{dagger},2* Jeffrey P. Hammel,1,{ddagger} Brenda B. Cirincione,1 Matthew A. Wikler,3 and Paul G. Ambrose1,2,{dagger}

Cognigen Corporation, Buffalo, New York,1 School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, New York,2 Peninsula Pharmaceuticals, Inc., Alameda, California3

Received 20 August 2004/ Returned for modification 12 January 2005/ Accepted 6 July 2005

A doripenem population pharmacokinetic model and Monte Carlo simulations were utilized for dose regimen decision support for future clinical development. Simulation results predict that 500 mg of doripenem administered over 1 h every 8 h would be effective against bacterial strains with MICs less than 2 µg/ml and that less susceptible strains could be treated with prolonged infusions.

* Corresponding author. Mailing address: Institute for Clinical Pharmacodynamics, Ordway Research Institute, 150 New Scotland Avenue, Albany, NY 12208. Phone: 518 641-6473. Fax: 518 641-6304. E-mail: SBhavnani-ICPD{at}OrdwayResearch.org.

{dagger} Present address: Institute for Clinical Pharmacokinetics, Ordway Research Institute, Albany, NY 12208.

{ddagger} Present address: Collaborative Biostatistics Center, Cleveland Clinic Foundation, Cleveland, OH 44195.

Antimicrobial Agents and Chemotherapy, September 2005, p. 3944-3947, Vol. 49, No. 9
0066-4804/05/$08.00+0     doi:10.1128/AAC.49.9.3944-3947.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Crandon, J. L., Bulik, C. C., Nicolau, D. P. (2009). In Vivo Efficacy of 1- and 2-Gram Human Simulated Prolonged Infusions of Doripenem against Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 53: 4352-4356 [Abstract] [Full Text]  
  • Baughman, R. P. (2009). The Use of Carbapenems in the Treatment of Serious Infections. J Intensive Care Med 24: 230-241 [Abstract]  
  • Cirillo, I., Vaccaro, N., Turner, K., Solanki, B., Natarajan, J., Redman, R. (2009). Pharmacokinetics, Safety, and Tolerability of Doripenem After 0.5-, 1-, and 4-Hour Infusions in Healthy Volunteers. J Clin Pharmacol 49: 798-806 [Abstract] [Full Text]  
  • Owens, R. C. Jr., Shorr, A. F. (2009). Rational dosing of antimicrobial agents: Pharmacokinetic and pharmacodynamic strategies. Am J Health Syst Pharm 66: S23-S30 [Abstract] [Full Text]  
  • Wagenlehner, F. M. E., Wagenlehner, C., Redman, R., Weidner, W., Naber, K. G. (2009). Urinary Bactericidal Activity of Doripenem versus That of Levofloxacin in Patients with Complicated Urinary Tract Infections or Pyelonephritis. Antimicrob. Agents Chemother. 53: 1567-1573 [Abstract] [Full Text]  
  • Cirillo, I., Mannens, G., Janssen, C., Vermeir, M., Cuyckens, F., Desai-Krieger, D., Vaccaro, N., Kao, L. M., Devineni, D., Redman, R., Turner, K. (2008). Disposition, Metabolism, and Excretion of [14C]Doripenem after a Single 500-Milligram Intravenous Infusion in Healthy Men. Antimicrob. Agents Chemother. 52: 3478-3483 [Abstract] [Full Text]  
  • Kim, A., Banevicius, M. A., Nicolau, D. P. (2008). In Vivo Pharmacodynamic Profiling of Doripenem against Pseudomonas aeruginosa by Simulating Human Exposures. Antimicrob. Agents Chemother. 52: 2497-2502 [Abstract] [Full Text]  
  • Burgess, D. S., Rapp, R. P. (2008). Bugs versus drugs: Addressing the pharmacist's challenge. Am J Health Syst Pharm 65: S4-S15 [Abstract] [Full Text]  
  • Ikawa, K., Morikawa, N., Urakawa, N., Ikeda, K., Ohge, H., Sueda, T. (2007). Peritoneal penetration of doripenem after intravenous administration in abdominal-surgery patients. J Antimicrob Chemother 60: 1395-1397 [Abstract] [Full Text]  
  • Ambrose, P. G., Forrest, A., Craig, W. A., Rubino, C. M., Bhavnani, S. M., Drusano, G. L., Heine, H. S. (2007). Pharmacokinetics-Pharmacodynamics of Gatifloxacin in a Lethal Murine Bacillus anthracis Inhalation Infection Model. Antimicrob. Agents Chemother. 51: 4351-4355 [Abstract] [Full Text]  
  • Lautenbach, E., Polk, R. E. (2007). Resistant gram-negative bacilli: A neglected healthcare crisis?. Am J Health Syst Pharm 64: S3-S21 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»